How do we manage t(11;14) plasma cell disorders with venetoclax?
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18243
Abstract: The oral BCL‐2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single‐agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial… read more here.
Keywords: manage plasma; cell; cell disorders; plasma cell ... See more keywords